Amgen Debuts Oncology Biosimilars Bevacizumab And Trastuzumab In US
Amgen has launched its Kanjinti biosimilar version of trastuzumab in the US after a court refused Genentech’s request for an injunction. At the same time, Amgen has also introduced its Mvasi bevacizumab biosimilar. The launches represent Amgen’s first biosimilar introductions in the US.
You may also be interested in...
Amgen Sued On US Stelara Biosimilar After Providing May 2023 Intent
With Janssen’s Stelara set to lose its exclusivity in September 2023, the originator is looking to ward off potential biosimilar competition from Amgen by suing the firm for patent infringement in a US district court.
Amneal Makes First Biosimilar Launch With US Bevacizumab
Amneal says it has “officially entered the US biosimilar market” after introducing its Alymsys biosimilar bevacizumab rival to Avastin. The biosimilar launch represents the first of three expected for Amneal in 2022, following US FDA approvals earlier this year.
Amgen Urges Adoption Of Balanced Policies For Biosimilars
A balanced policy environment that can support biosimilar competition is needed to allow the drugs to flourish in the US, says Amgen’s executive director of marketing and global biosimilars commercial lead Chad Pettit.